Global Molecular Diagnostics Market for Infectious Disease Analysis and Executive Guides 2023-2027: Assessing the Growing Demand for Rapid Diagnostic Solutions in Various Healthcare Settings - ResearchAndMarkets.com

13 Feb 2024
www.businesswire.com
DUBLIN--(BUSINESS WIRE)--The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With Analysis and Executive Guides. 2023-2027" report has been added to ResearchAndMarkets.com's offering.
'Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With Analysis and Executive Guides. 2023-2027'
In a Post Pandemic world molecular diagnostics sees technologies boom. Nucleic acids become key.
The global market for molecular diagnostics (MDx) in infectious diseases is analyzed across various dimensions in this report. It begins with an overview of the global market by country, providing insights into regional trends and dynamics. The market is further segmented by syndrome, offering detailed analysis of key areas such as respiratory, gastrointestinal, blood, meningitis/encephalitis, sexually transmitted diseases, and others.
Additionally, the report examines the market by plex, distinguishing between single plex, duplex, triplex, and multiplex technologies and their respective market landscapes. Furthermore, the analysis extends to different places where MDx testing is conducted, including hospital labs, outpatient labs, point-of-care settings, and other locations.
This comprehensive examination provides valuable insights into the global MDx infectious disease markets, enabling stakeholders to make informed decisions and capitalize on emerging opportunities.
The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.
Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations.
Trends like:
Multiplex testing
Pathogen evolution and pandemics
Biotechnology advances in genetics
Climate change
Globalization
The rise of rapid testing
Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.
The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.
Key Topics Covered:
1 Market Guides
1.1 Strategic Situation Analysis
1.2 Guide for Executives and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 What are Molecular Diagnostics?
2.2 The Diagnostics Revolution
2.3 Market Definition
2.3.1 Revenues
2.4 Methodology
2.4.1 Methodology
2.4.2 Sources
2.4.3 Authors
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics
3 The Infectious Diseases - Market Analysis by Disease
3.1 HIV - Human Immunodeficiency Virus (AIDS)
3.1.1 Virology
3.1.1.1 Classification
3.1.1.2 Structure and Genome
3.1.1.3 Tropism
3.1.1.4 Replication cycle
3.1.1.5 Genetic variability
3.1.2 Diagnosis
3.1.3 Testing
3.1.3.1 Antibody tests
3.1.3.2 Point of Care Tests (POCT)
3.1.3.3 Antigen Tests
3.1.3.4 Nucleic acid-based tests (NAT)
3.1.3.5 Other tests used in HIV treatment
3.1.4 Market Opportunity Analysis
3.2.1 Virology
3.2.1.1 Genome
3.2.1.2 Pathogenesis
3.2.1.3 Hepatitis B virus replication
3.2.1.4 Serotypes and genotypes
3.2.2 Mechanisms
3.2.3 Diagnosis
3.2.4 Market Opportunity Analysis
3.3.1 Taxonomy
3.3.2 Structure
3.3.2.1 Genome
3.3.3 Molecular biology
3.3.4 Replication
3.3.5 Genotypes
3.3.5.1 Clinical importance
3.3.6 Market Opportunity Analysis
3.4 HPV - Human papillomavirus
3.4.1 Virology
3.4.1.1 E6/E7 proteins
3.4.1.2 Role in Cancer
3.4.1.3 E2 research
3.4.1.4 Latency period
3.4.1.5 Clearance
3.4.2 Diagnosis
3.4.2.1 Cervical testing
3.4.2.2 Oral testing
3.4.2.3 Testing men
3.4.2.4 Other testing
3.4.3 Market Opportunity Analysis
3.5.1 Virology
3.5.1.1 Types of virus
3.5.1.2 Influenzavirus A
3.5.1.3 Influenzavirus B
3.5.1.4 Influenzavirus C
3.5.1.5 Structure, properties, and subtype nomenclature
3.5.1.6 Replication
3.5.2 Testing
3.5.2.1 Advantages/Disadvantages of Molecular Assays
3.5.3 Market Opportunity Analysis
3.6 CTGC - Chlamydia/Gonorhea
3.6.1 Gonorrhea
3.6.1.1 Diagnosis
3.6.1.2 Screening
3.6.2 Chlamydia
3.6.2.1 Diagnosis
3.6.2.2 Screening
3.6.3 Testing
3.6.3.1 Nucleic acid amplification tests (NAATs).
3.6.3.2 Performance of NAAT Tests
3.6.4 Market Opportunity Analysis
3.7.1 Mycobacteria
3.7.2 Diagnosis
3.7.2.1 Active tuberculosis
3.7.3 Epidemiology
3.7.4 Molecular Diagnostic Tests
3.7.5 Market Opportunity Analysis
3.8 MRSA - Methicillin-resistant Staphylococcus aureus
3.8.1 Diagnosis
3.8.2 FDA Approved Molecular Tests
3.8.3 Market Opportunity Analysis
3.9 VRE - Vancomycin-resistant Enterococcus
3.9.1 FDA-Approved MDx Tests for VRE
3.9.2 Market Opportunity Analysis
3.10 Blood Screening
3.10.1 Collection and Testing
3.10.2 FDA Approved Multiplex Assays
3.10.3 Market Opportunity Analysis
3.11.1 Signs and symptoms
3.11.2 Transmission
3.11.3 Diagnosis
3.11.4 Prevention
3.11.5 Management
3.11.6 Prognosis
3.12 Pandemic Diagnostics
3.12.1 Risk Management - Spark and Spread
3.12.2 Dx Technology - Nucleic Acid-Based
3.12.3 Dx Technology - Immunoassay & Serology
3.12.4 Time to Market and Preparedness Issues
3.12.5 Unrecognized Role of Multiplex in Pandemic Management
4 Industry Overview
4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Instrumentation Supplier
4.1.4 Chemical/Reagent Supplier
4.1.5 Pathology Supplier
4.1.6 Independent Clinical Laboratory
4.1.7 Public National/regional Laboratory
4.1.8 Hospital Laboratory
4.1.9 Physicians Office Lab (POLS)
4.1.10 Audit Body
4.1.11 Certification Body
4.2 The Clinical Laboratory Market Segments
4.2.1 Traditional Market Segmentation
4.2.2 Laboratory Focus and Segmentation
4.3 Industry Structure
4.3.1 Hospital Testing Share
4.3.2 Economies of Scale
4.3.2.1 Hospital vs. Central Lab
4.3.3 Physician Office Lab's
4.3.4 Physicians and POCT
5 Profiles of Key MDx Companies
6 Market Trends
6.1 Factors Driving Growth
6.1.1 New Genotypes Creating New Markets
6.1.2 The Aging Effect
6.1.3 Developing World Driving ID Dx Growth
6.1.4 Point of Care - Why Centralization is Losing Steam
6.1.5 Self Testing
6.1.6 The Need for Speed
6.1.7 The COVID Pandemic
6.2 Factors Limiting Growth
6.2.1 Lower Costs
6.2.2 Infectious Disease is Declining
6.2.3 Wellness Hurts
6.2.4 Economic Growth Improves Living Standards
6.3 Instrumentation and Automation
6.3.1 Instruments Key to Market Share
6.3.2 The Shrinking Machine
6.3.3 Multiplex, Point of Care, and The Speed Factor
6.4 Diagnostic Technology Development
6.4.1 The Sepsis Testing Market - A New Direction?
6.4.2 POCT/Self Testing as a Disruptive Force
6.4.3 The Genetics Play - One Test for All Known Infections
6.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics
7 Molecular Dx - Infectious Disease Recent Developments
7.1 Recent Developments - Importance and How to Use This Section
7.1.1 Importance of These Developments
7.1.2 How to Use This Section
Company Profiles
ADT Biotech
Anatolia Geneworks
Applied BioCode
Aus Diagnostics
BioFire Diagnostics (bioMerieux)
Celemics
Cepheid (Danaher)
Chembio
Cue Health
Curetis N.V. / Curetis GmbH
Detect
Diascopic
Fluxergy
Genetic Signatures
Hologic
Immunexpress
LumiraDx
Mesa Biotech (Thermo Fisher)
Millipore Sigma
Mindray
Mobidiag (Hologic)
NanoDx
Novel Microdevices
Pathogenomix
Perkin Elmer
Prenetics
Primerdesign (Novacyt)
Saw Diagnostics
Scope Fluidics
SD Biosensor
Seegene
Siemens Healthineers
Sona Nanotech
Vir
For more information about this report visit https://www.researchandmarkets.com/r/twbxfg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.